Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis

Prior treatment

• Pregnancy, lactation, and those who are not pregnant but did not, or unwilling to, take effective contraceptives measures 4 weeks before and after the treatment.
• Patients who have immuno-compromised condition or is with known clinically significantly autoimmune conditions other than MS or is receiving immunosuppressive treatments other than MS treatment within 6 months.
• Patients who are participating in other clinical trials with an investigational product within 1 month.
• Patients who were treated with cytotoxic medications during the last 1 month prior to the infusion.
• Relapse of MS within1 month before UMSC01 infusion.
• With anti-CD20 therapy, such as rituximab

Other illness

• Patients who have medical history or current clinically active malignant tumor, peripheral neuropathy, myopathy or other clinically significant neurological diseases that will confound the evaluation of this study.
• With active infection that required systemic treatment

Lab values

• Patients with uncontrolled diabetes (fasting blood glucose \> 250 mg/dL)
• Patients with inadequate hepatic and renal function: AST and ALT \> 5X ULN; eGFR \< 30 mL/min.

Other

• Patients who are unable to undergo Brain MRI examination for any reason.
• Patients not suitable to participate the trial as judged by the Investigator(s)

• Patients are willing to sign informed consent.
• Male or female are age between 20 to 65 years old on date of consent.
• Diagnosis of Relapsing-Remitting MS (RRMS) (≥1 clinically documented relapse in the past 12 months, ≥2 clinically documented relapses in the last 24 months or ≥ 1 gadolinium enhanced lesion or T2 new lesion in the last 12 months) or Secondary Progressive MS (SPMS) (EDSS increase ≥1.0 point (baseline EDSS ≤ 5.0) or ≥ 0.5 point (baseline EDSS ≥5.5), and ≥1 clinical relapse or ≥1 gadolinium enhanced lesion in the last 12 months)
• MS diagnosis established between 2 to 15 years and EDSS score between 2.0 to 6.5 before enrollment
• Patient has appropriated blood clotting function as assessed by the following laboratory requirements: PT, APTT ≤ 1.5X upper limit of normal (ULN).
• Treatment failure (either ≥ 1 relapse, ≥ 1 new T2 lesion, ≥ one gadolinium enhanced lesion or EDSS deterioration) with at least one of MS disease modifying therapy as Interferon-β, Glatiramer acetate (Copaxone), Dimethyl fumarate (Tecfidera), Teriflunomide (Aubagio), Fingolimod (Gilenya), Ozanimod (Zeposia), Cladribine (Mavenclad), Siponimod (Mayzent), Ofatumumab (Kesimpta), or Natalizumab (Tysabri) for more than 6 months
• All male patients and female patients with child-bearing potential (between puberty and 2 years after menopause) should use appropriate contraception method(s) for at least 4 weeks after UMSC01 treatment